A multi-centre double-blind randomized study is reported in which the effect on mortality of oral disopyramide (300 mg loading dose, then 100 mg qds) was compared with placebo in 1985 patients entering hospital with suspected acute myocardial infarction. Treatment was commenced with 24 hr of onset of symptoms (mean time to first dose 9 hr) and continued until discharge from hospital or 14 days, whichever came first. Nine-hundred and ninety-five patients were allocated to disopyramide and 990 to placebo. The overall mortality, calculated on an intention-to-treat basis, was 7-2% for the disopyramide and 5-6% for the placebo patients. Among those patients with proven infarction mortality was 9 5% of 687 on disopyramide and 7-4% of 716 on placebo. These differences are not statistically significant. Patients with cardiac failure or hypotension at entry did not fare worse on disopyramide, but those with a conduction defect did. Reinfarction was not significantly influenced by disopyramide. The prophylactic use of disopyramide in patients with suspected acute myocardial infarction does not reduce mortality or the incidence of early reinfarction.
Introduction
Arrhythmias contribute substantially to the mortality of acute myocardial infarction (AMI), especially in the first 24 hr (Engler and LeWinter, 1982) . Disopyramide is a proven anti-arrhythmic agent (Koch-Weser, 1979 ) and there have been four studies of its effect on survival after AMI (Jennings et al., 1976; Zainal et al., 1977; Nicholls, Haybyrne and Barnes, 1980; Wilcox et al., 1980) . In the first study (Jennings et al., 1976 ) of 95 patients with proven AMI admitted to a Coronary Care Unit, there was evidence of an anti-arrhythmic effect but no significant difference in mortality with disopyramide compared with placebo. Another small study (Zainal et al., 1977) with patients treated in an open ward showed a dramatic reduction in mortality with 11 deaths on placebo compared with one on disopyramide. This study was strongly criticized (Dollery, Krikler and Shillingford, 1977; Greenbaum, 1977; Julian, 1977; Pottage, Pickens and Robson, 1977a, b) and there were calls (Anonymous, 1977; Julian, 1977; Goldman and Inglefinger, 1978) for a larger and better designed study.
Since the inception of our trial, two studies (Nicholls et al., 1980; Wilcox et al., 1980) have been published which failed to confirm the earlier findings but we believe from our calculations that these were much too small, as acknowledged by Nicholls et al. (1980) . Our large multi-centre trial of oral disopyramide given to patients admitted to hospital with suspected AMI was designed to determine whether disopyramide can reduce mortality in this situation. The number of patients required was estimated. Where the electrocardiographic evidence suggested subendocardial infarction, it was deemed necessary that the enzymatic criteria should also be satisfied. Clear necropsy evidence of recent AMI or coronary arterial occlusion was accepted as evidence of myocardial infarction for the purposes of this study, regardless of whether the aforementioned criteria were satisfied. The diagnosis of reinfarction rested on the same criteria as those used for the initial infarction.
Trial treatment could be withdrawn at any time at the discretion of the local investigator and the timing and reason for all such withdrawals were recorded. Patients were to be withdrawn from the study if the diagnosis of AMI was not confirmed, if hypotension (systolic blood pressure s70 mmHg) developed with evidence of low cardiac output, or if apparent side effects from the trial medication were troublesome.
Trial design
The primary objective of the study was to evaluate the prophylactic effect of oral disopyramide on mortality in patients with AMI managed in hospital. It was a double-blind, placebo-controlled multicentre study and at each centre treatment was randomly allocated in pairs (one patient of the pair receiving disopyramide and the other placebo) in order to balance the number of patients receiving each form of treatment at each hospital. The patients remained in the trial until one of the pre-determined end-points was reached and these were death, discharge from hospital, or 14 days after entry to the trial. Withdrawal of treatment, although recorded, was not an end-point.
With symmetrical error rates at 5% significance and 95% power, a reduction in mortality from 17-0% to 8-5% would need 390 subjects per treatment group. If the error rates are tightened up to 1% significance and 99% power the numbers per treatment group are approximately doubled. On statistical advice a minimum inclusion of 1,000 patients with confirmed AMI was proposed and a modification of the group sequential block design of Pocock (1977) adopted in which the initial significance test was performed when 1,000 patients had been entered and subsequent tests performed at the completion of every additional block of 100 patients up to a maximum of 2,000 patients. Mortality in the active and placebo groups was compared using the chi-square test of the 2-by-2 contingency table and the nominal significance level to be used in the repeated significance tests (McPherson, 1974) 
Comparability
The characteristics at entry are set out in Table 1 . These groups are broadly similar apart from significantly more disopyramide patients having been on a diuretic prior to entry (P<0-01), significantly more placebo patients having ventricular arrhythmia at entry (P<0 01), and significantly more disopyramide patients with an interval of more than 8 hr between onset of symptoms and first dose of trial medication (P<0 05). In Table 2 the diagnostic categories are listed for the two treatment groups. Again, a similar pattern is evident in the two groups with only slight differences in terms of the site of infarction, diagnosis where AMI was not confirmed, and in the ratio of confirmed to non-confirmed AMI.
Mortality
Analysis proceeded according to the modified Pocock design from entry of 1,000 patients onwards. When 1,300 patients with confirmed AMI had been entered, 63 of 635 disopyramide patients and 51 of 665 placebo patients were found to have died; this represented mortality rates of 9-92% and 7T67% respectively, a difference of 225% in favour of placebo. This difference has a 95% confidence interval from 0-83% in favour of disopyramide to 5 33% in favour of placebo. The difference was not statistically significant at the 5% level, and the best result in favour of disopyramide consistent with these data was a mere 0-83% improvement in mortality. To confirm this possibility with type I and II error rates of 5% would have required over 30,000 patients per group. It was therefore decided to discontinue the trial at this stage, especially as the balance of probability was in favour of placebo. The numbers finally available for analysis were slightly increased because of recruitment to the study whilst analysis was being carried out, before the investigators were advised to cease entry of further patients.
The final analysis is presented in Fig. 1 in the format advocated by Hampton (1981) , distinguishing between the patients with and without confirmed AMI. It should be noted that treatment was usually withdrawn in the cases where AMI was not confirmed and these patients generally had a shorter stay in hospital as they tended to be discharged once the investigator had established that they had not suffered AMI. The final overall mortality in the two groups was 7 2% for disopyramide and 5 6% for placebo treatment, and among cases with confirmed AMI 9 5% and 7-4% respectively. Six of the deaths among patients in whom AMI was not confirmed were clinically believed to be due to myocardial infarction but the patients died before sufficient data could be accumulated to establish infarction according to trial criteria and conclusive necropsy evidence was lacking. Because of this and the small numbers in these groups, percentage mortality rates were not calculated as these might be misleading. The greater mortality among patients in whom treatment was withdrawn, both for disopyramide and for placebo groups, would be anticipated because indications for withdrawal included certain clinical developments which signal a worsening situation.
The time of death after commencement of treatment was similar for the two treatment groups (Table  3) , with the greatest mortality occurring as expected during the first 24 hr.
The causes of death are presented in Table 4 , and the spectrum of clinical events is that which would be expected in patients admitted to hospital with sus- Table 5 the only subgroups which appear to fare significantly worse on disopyramide are those with anterior infarction and those with conduction defect at entry.
Because of concern over cardiac failure with the use of disopyramide we examined the possible association between cardiac failure and the highest risk factor identified in the subgroup analysis, namely conduction defect on entry. The results are presented in Table 6 and show that where patients with cardiac failure at entry were treated with disopyramide the excess mortality compared with placebo treatment is attributable to the additional presence of conduction defect.
Withdrawals
Reasons for withdrawal are given in Table 7 . The majority of patients in whom AMI was not confirmed had their treatment withdrawn as specified in the trial protocol, and of these 81% who had been taking disopyramide and 6-9% who had been on placebo left hospital immediately.
In 17 cases in the disopyramide group and nine in the placebo group an adverse effect occurred which resulted in withdrawal of trial therapy, regardless of the fact that AMI was not subsequently confirmed. Among the group with confirmed AMI 119 patients (17-3%) in the disopyramide group and 106 (14 8%) in the placebo group had their treatment withdrawn.
The only significant differences between disopyramide and placebo treatment in terms of reasons for withdrawal were in respect of heart block and urinary retention among patients with confirmed AMI (P<005 in both cases). Cardiac failure and cardiogenic shock were slightly, but not significantly, less of a problem in patients treated with disopyramide than in patients treated with placebo where AMI was confirmed and, as might be expected, such haemodynamic disturbances hardly featured in the reasons for withdrawal among patients in whom AMI was not confirmed.
Events other than death during the trial (Table 8) The most significant difference between the treatment groups was in respect of arrhythmias other than ventricular fibrillation, ventricular tachycardia, and asystole in patients with confirmed AMI (P<0 01, in favour of disopyramide). Although ventricular fibrillation and ventricular tachycardia occurred less frequently in patients with confirmed AMI treated with disopyramide, the difference was not significant; however, ventricular arrhythmias were also less common in the disopyramide group at entry (Table  1) . Disopyramide treatment in patients with confirmed AMI showed a lower incidence of development of cardiac failure compared with placebo (39) treatment (9-8% v. 11-6%), but again this difference was not significant. The greater number of patients developing urinary difficulties on disopyramide treatment was expected, in view of the anti-cholinergic properties of the drug (Koch-Weser, 1979 ), but the difference achieved statistical significance only in the patients with confirmed AMI (4 5% with disopyramide v. 2-4% with placebo, P<0-05). Only one other clinical feature proved statistically significant between the treatment groups, and that was the occurrence of thromboembolic problems in patients with confirmed AMI (3-1% with disopyramide v. 1[3% with placebo, P< 0 05).
Discussion
In this study of 1985 patients admitted to hospital with suspected AMI, and fulfilling certain criteria, there was no demonstrable difference in mortality with routine use of oral disopyramide compared with placebo. It appears that the active and placebo' treatment groups were fairly well matched in terms of characteristics before treatment (Table 1) , the pro- (173) 106 (148) 289 (938) 255 (93 1) tP<0-05. AMI = acute myocardial infarction; NA = not applicable. portion of the group in whom AMI was confirmed and the site of infarction (Table 2) . We believe that the results of this large study effectively and authoritatively negate the findings in the two earlier smaller studies (Jennings et al., 1976; Zainal et al., 1977) . This reinforces the point that small studies, especially where flaws have been identified in the design or execution, should never be taken as the basis for the major change in prescribing habits such as starting to use a drug routinely for prophylaxis. Not only did we fail to confirm the observation that disopyramide was associated with a significant reduction in mortality (Zainal et al., 1977) , but also we failed to confirm (Table 8 ) the reported significant reduction in early reinfarction (Jennings et al., 1976; Zainal et al., 1977) . The previously reported significant reduction in ventricular arrhythmias (Jennings et aL, 1976; Zainal et al., 1977) and all types of atrioventricular block (Jennings et al., 1976) could not be confirmed in the defined categories of ventricular fibrillation, ventricular tachycardia, asystole and conduction disturbance in our study (Table 8 ). In our group with confirmed AMI ventricular fibrillation occurred in 1 9% of patients on disopyramide and 3-1% of patients on placebo; these differences were not significant and it must be remembered that ventricular arrhythmias were more common in the placebo group at entry. However, we did find that other arrhythmias were less common in the disopyramidetreated group with confirmed AMI (5-8% on disopyramide v. 9-8% on placebo, P<001).
Decreased mortality with use of fl-blocker drugs as secondary prophylaxis after AMI has been demonstrated over study periods ranging from 3 to 48 months in a number of placebo-controlled trials published in the last decade (Staessen et al., 1982) .
Two of these trials which recently received considerable attention were the timolol trial from Norway (Norwegian Multicentre Study Group, 1981) and the propranolol trial from the United States (,8-blocker Heart Attack Study Group, 1981) ; both showed significant reduction in mortality for the groups receiving the f8-blocker but entry to the trials was not until 5 to 28 days postinfarction and the influence on mortality was measured over an average follow-up of 17 months (timolol) and 25 months (propranolol) . Thus, in comparison to our disopyramide study they represent later starts and very much longer study periods. There has, however, been one fl-blocker trial with a very early start and that was the Goteborg study in which intravenous metoprolol or placebo was given at a mean interval of 11 hr from onset of pain, and the patients then continued on oral treatment for 90 days (Hjalmarson et al., 1981 Hjalmarson et al., 1981) . The difference between the groups appeared and widened gradually between day 5 and day 40, after which the mortality plots for both groups remained roughly parallel. Therefore it is possible that reduction in mortality after AMI may not be very impressive in early-phase short-term trials, such as ours, even when drugs which confer benefit over longer-term administration are used. Our failure to reduce mortality among the patients receiving disopyramide prompts consideration of whether our patients had adequate plasma levels of the drug, particularly in the early phase when mortality is greatest. We based our dosage on the recommendation of Ward and Kinghorn (1976) who had studied the kinetics of disopyramide in AMI and suggested a loading dose of 300 mg, but subsequent reports have cast some doubt on the adequacy of this (Ilett, Madsen and Woods, 1979; Weissberg et aL, 1981) .
Of concern during our study was the report from the United States of frequently encountered precipitation of new congestive cardiac failure or aggravation of pre-existing cardiac decompensation with disopyramide (Podrid, Schoeneberger and Lown, 1980) . If cardiac failure had occurred in the past, there was a substantial risk of recurrence with disopyramide. The Nottingham group had also reported in their 6-week post-infarction study that there were significantly more withdrawals from the disopyramide phosphate-treated group for heart failure (Wilcox et al., 1980) . Our own results, like those of the Salford group (Nicholls et al., 1980) , indicate that disopyramide is not associated with the hazard suggested by the group from the United States (Podrid et aL, 1980) . The data on cardiac failure have been considered in some detail because of the obvious clinical importance of our experience in almost 2,000 patients. Cardiac failure was given as a reason for withdrawal in only four of the patients treated with disopyramide compared with eight on placebo treatment; corresponding figures for hypotension and cardiogenic shock are 14 patients receiving disopyramide and 14 patients receiving placebo (Table 7) . Deaths among patients with evidence of cardiac failure at entry to the study (Table 5) were slightly, but not significantly, higher in the disopyramide group and the difference is accounted for almost entirely by the further subgroups with co-existing conduction defect in which the mortality was 62 9% on disopyramide compared with 261% on placebo. Our data do not allow identification of the mechanism underlying increased mortality when disopyramide was given to patients with both cardiac failure and conduction defect but, as already suggested by Desai et al. (1981) , disopyramide could be exerting a diffuse toxic effect on both sinus node and junctional automaticity and on conduction in both the specialized cardiac conduction system and the ventricular muscle. We disagree strongly with the blanket condemnation (Podrid et al., 1980) of disopyramide treatment in patients with past or present cardiac failure and would not wish to see this generally useful anti-arrhthymic drug (Heel et al., 1978; Koch-Weser, 1979) unnecessarily withheld from patients. especially where there are serious rhythm disturbances which have already proven refractory to other therapy (Vismara et al., 1977) . Rather, we would urge recognition of the evident hazard of using disopyramide in patients with conduction defect, whether or not cardiac failure is present (Table 6) .
Our data, like those from the recent smaller studies (Nicholls et al., 1980; Wilcox et al., 1980) , indicate that disopyramide does not reduce mortality among patients admitted to hospital with suspected AMI. Even if the high-risk subgroup of patients with cardiac failure and conduction defect were to be excluded we do not have convincing evidence for using disopyramide prophylactically in this situation.
